Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From IFM Tre
The company has assembled small molecule discovery capabilities for the development of targeted cancer drugs that it believes rivals big pharma efforts and will fulfill patients’ unmet needs.
Having acquired Jecure Therapeutics and its preclinical portfolio of NLRP3 inhibitors just under two years ago, the Swiss giant has swooped in to buy Dublin-based Inflazome and expand its presence in a hot field of inflammatory research.
Swiss pharma thinks targeted integrin inhibition could be part of the approach to treating cirrhotic NASH patients, those most at risk of needing a liver transplant.
UK-headquartered company gets further backing from Novo Ventures and other investors convinced of the potential of NLRP3 inhibitors.
- Other Names / Subsidiaries
- IFM Due
- IFM Therapeutics